Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans

被引：10

作者：

Barton, Pelham ^{[1
]}

机构：

[1] Univ Birmingham, Hlth Econ Unit, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England

来源：

RHEUMATOLOGY | 2011年 / 50卷

关键词：

Rheumatoid arthritis; NICE; Modelling; Biologic therapies; Cost-effectiveness analysis; TUMOR-NECROSIS-FACTOR; ETANERCEPT; ADALIMUMAB; INFLIXIMAB; ADULTS;

D O I：

10.1093/rheumatology/ker244

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

The Birmingham Rheumatoid Arthritis Model (BRAM) has been developed over a number of years to inform several appraisals of biologic drugs by the Technology Appraisals Committee of the UK National Institute for Health and Clinical Excellence. This article describes the processes used in the construction of the different versions of the BRAM.

引用

页码：iv32 / iv38

页数：7

共 7 条

[1]

Barton P, 2004, HEALTH TECHNOL ASSES, V8, P1

[2]

BARTON P, 2008, FURTHER COST EFFECTI

[3]

Barton Pelham, 2004, J Health Serv Res Policy, V9, P110, DOI 10.1258/135581904322987535

[4]

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness [J].

Chen, Y-F ;

Jobanputra, P. ;

Barton, P. ;

Jowett, S. ;

Bryan, S. ;

Clark, W. ;

Fry-Smith, A. ;

Burls, A. .

HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (42) :1-+

[5]

Clark W, 2004, HEALTH TECHNOL ASSES, V8, P1

[6]

Jobanputra P, 2002, HEALTH TECHNOL ASSES, V6, P1, DOI DOI 10.3310/hta6210

[7]

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation [J].

Malottki, K. ;

Barton, P. ;

Tsourapas, A. ;

Uthman, A. O. ;

Liu, Z. ;

Routh, K. ;

Connock, M. ;

Jobanputra, P. ;

Moore, D. ;

Fry-Smith, A. ;

Chen, Y-F .

HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (14) :1-+

← 1 →